Patch Testing Ingredients of Dermabond and Other Cyanoacrylate-Containing Adhesives.
CONCLUSIONS: Octyl cyanoacrylate is the usual allergenic ingredient in Dermabond. Patch testing with high concentrations is often required. Testing Dermabond on abraded skin further improves diagnostic sensitivity by more closely simulating clinical use. PMID: 31517667 [PubMed - as supplied by publisher]
ConclusionIn this racially diverse cohort, higher 2nd trimester n-6 PUFAs were associated with atopic dermatitis in children of women with atopy. PUFAs may represent a modifiable risk factor for atopic dermatitis, particularly in individuals with a familial predisposition.
Capsule Summary: Ruxolitinib cream improved Eczema Area Severity Index and Investigator ’s Global Assessment responses in patients with atopic dermatitis (AD), with rapid, sustained improvement in itch. Ruxolitinib cream may offer a novel and effective treatment for AD.
CONCLUSION AND CLINICAL IMPORTANCE: This study demonstrates that a shorter EDT is possible if the allergic pruritus and inflammation are initially controlled with a short course of glucocorticoids. This shortened trial is likely to improve owner adherence and facilitate the diagnosis of food allergy. PMID: 31617265 [PubMed - as supplied by publisher]
For this ‘From the Pages of Allergy Watch’ reviews from several recent issues were selected which review articles about Allergic Skin Diseases, the focus of this issue of the Annals. The first article describes a unique minimally invasive method of skin tape stripping to identify infants with atopic derm atitis who are at increased risk for food allergy. The next study investigates the difference between IgE sensitivity and clinical reactivity to foods in children with atopic dermatitis. The last investigates the impact of UV light exposure and the development of atopic dermatitis in infancy.
CONCLUSIONS: The prevalence of p-phenylenediamine allergy remains high among patients with contact eczema. Risk factors for p-phenylenediamine contact allergy are consistent with previous reports. PMID: 31627850 [PubMed - as supplied by publisher]
The circulating immune phenotype was defined in adults and young children with early atopic dermatitis/AD, but chronologic changes in blood of AD infants and children through adolescence have not been explored.
Atopic dermatitis (AD) is associated with increased systemic inflammation and cardiovascular risk. While previous studies showed increased inflammatory proteins in the blood of AD patients, detailed comparison among AD patients of different ages is unavailable.
Filaggrin is a major epidermal protein that has been shown to be a key player in the pathogenesis of AD and allergic disease. While filaggrin is a significant genetic risk factor for AD, it is also an important disease modifier in AD. Patients with filaggrin related AD and asthma have more frequent hospital admissions and long-term medication costs. Atopic dermatitis patients with FLG mutations are more frequently affected by reduced health related quality of life when compared to AD patients with wild-type FLG.
Disclosures: E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, N...
PMID: 31622670 [PubMed - as supplied by publisher]